Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15645028 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2SMYD2CYP3A4HTTMAOA | |
| SCHEMBL31400145 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2SMYD2CYP3A4HTTMAOA | |
| SCHEMBL3939837 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2SMYD2CYP3A4HTTMAOA | |
| SCHEMBL2818126 | 0.95 | SMN1; SMN2 (0.38) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL12987807 | 0.90 | SMYD2 (0.33) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL12988245 | 0.90 | SMYD2 (0.33) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL15644367 | 0.90 | SMYD2 (0.33) | SMN1; SMN2SMYD2CYP3A4HTT | |
| Butylamine SCHEMBL20954570 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL453430 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL4863255 | 0.87 | IDO1 (0.42) | SMN1; SMN2SMYD2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638417-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| US-20250304547-A1 | Sulfur-Containing Lipids | NANOVATION THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| EP-4594300-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025035202-A1 | IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-12-05 | — | — | US | disclosed |
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | NANOVATION THERAPEUTICS INC. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240294462-A1 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | NANOVATION THERAPEUTICS INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-08-08 | — | — | US | disclosed |
| WO-2024130421-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024065041-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-04-04 | — | — | WO | disclosed |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2003-05-15 | — | — | US | disclosed |
| CN-1409720-A | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORP (US) | 2003-04-09 | — | — | CN | disclosed |
| EP-1230250-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| WO-2001034617-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | SLC43A1, NSUN3, NSUN2 | SMN1; SMN2 919/4885SMYD2 413/4885CYP3A4 4678/4885 |
| US-20020048588-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | SMN1; SMN2 4820/4885SMYD2 2362/4885CYP3A4 3571/4885 |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | SMN1; SMN2 919/4885SMYD2 413/4885CYP3A4 4678/4885 |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | SMN1; SMN2 4817/4885SMYD2 2464/4885CYP3A4 3535/4885 |
| US-20240294462-A1 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | SGMS1, SGMS2, LIPC | SMN1; SMN2 4587/4885SMYD2 1015/4885CYP3A4 934/4885 |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | SMN1; SMN2 919/4885SMYD2 413/4885CYP3A4 4678/4885 |
| US-20250304547-A1 | Sulfur-Containing Lipids | FABP1, SLC10A1, MPST | SMN1; SMN2 1685/4885SMYD2 475/4885CYP3A4 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.